Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy
Download full text from publisher
Other versions of this item:
- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical industry, drug quality and regulation. Evidence from US and Italy," CEIS Research Paper 138, Tor Vergata University, CEIS, revised 16 Dec 2008.
References listed on IDEAS
- Bernardo Batiz-Lazo & k Sarah Holland, 2004. "The Global Pharmaceutical Industry, 2004," General Economics and Teaching 0405002, EconWPA.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005.
"The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s,"
John Wiley & Sons, Ltd., vol. 14(3), pages 269-292.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2003. "The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s," NBER Working Papers 9874, National Bureau of Economic Research, Inc.
- Armstrong, Mark & Vickers, John, 1993. "Price Discrimination, Competition and Regulation," Journal of Industrial Economics, Wiley Blackwell, vol. 41(4), pages 335-359, December.
- Enrico Pennings, 2004.
"Optimal Pricing And Quality Choice When Investment In Quality Is Irreversible,"
Journal of Industrial Economics,
Wiley Blackwell, vol. 52(4), pages 569-589, December.
- Enrico Pennings, "undated". "Optimal pricing and quality choice when investment in quality is irreversible," Working Papers 206, IGIER (Innocenzo Gasparini Institute for Economic Research), Bocconi University.
- Bhattacharya, Jayanta & Vogt, William B, 2003. "A Simple Model of Pharmaceutical Price Dynamics," Journal of Law and Economics, University of Chicago Press, vol. 46(2), pages 599-626, October.
- Ernst R. Berndt, 2002. "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 45-66, Fall.
- Dale T. Mortensen & Randall Wright, 2002. "Competitive Pricing and Efficiency in Search Equilibrium," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 43(1), pages 1-20, February.
- Marisa Miraldo, 2007. "Reference Pricing Versus Co-Payment in the Pharmaceutical Industry: Price, Quality and Market Coverage," Working Papers 025cherp, Centre for Health Economics, University of York.
- Toshimitsu, Tsuyoshi, 2003. "Optimal R&D policy and endogenous quality choice," International Journal of Industrial Organization, Elsevier, vol. 21(8), pages 1159-1178, October.
- Light, Donald W. & Warburton, Rebecca N., 2005. "Extraordinary claims require extraordinary evidence," Journal of Health Economics, Elsevier, vol. 24(5), pages 1030-1033, September.
- Berndt Ernst R. & Gottschalk Adrian H. B. & Philipson Tomas & Strobeck Matthew W., 2005.
"Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process,"
Forum for Health Economics & Policy,
De Gruyter, vol. 8(1), pages 1-25, January.
- Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson, 2005. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," NBER Chapters,in: Frontiers in Health Policy Research, Volume 8 National Bureau of Economic Research, Inc.
- Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck, 2004. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," NBER Working Papers 10822, National Bureau of Economic Research, Inc.
- Jean-Pierre Nadal & Denis Phan & Mirta Gordon & Jean Vannimenus, 2005.
"Multiple equilibria in a monopoly market with heterogeneous agents and externalities,"
Taylor & Francis Journals, vol. 5(6), pages 557-568.
- Denis Phan & Mirta Gordon & J.-P. Nadal & J. Vannimenus, 2005. "Multiple equilibria in a monopoly market with heterogeneous agents and externalities," Post-Print halshs-00078792, HAL.
- Peltzman, Sam, 1973. "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments," Journal of Political Economy, University of Chicago Press, vol. 81(5), pages 1049-1091, Sept.-Oct.
- Gordon, Mirta B. & Nadal, Jean-Pierre & Phan, Denis & Vannimenus, Jean, 2005.
"Seller's dilemma due to social interactions between customers,"
Physica A: Statistical Mechanics and its Applications,
Elsevier, vol. 356(2), pages 628-640.
- Mirta Gordon & Jean-Pierre Nadal & Denis Phan & Jean Vannimenus, 2005. "Sellers dilemna due to social interactions between customers," Post-Print halshs-00078451, HAL.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2005. "Extraordinary claims require extraordinary evidence," Journal of Health Economics, Elsevier, vol. 24(5), pages 1034-1044, September.
- David Sappington, 2005. "Regulating Service Quality: A Survey," Journal of Regulatory Economics, Springer, vol. 27(2), pages 123-154, November.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
- Besanko, David & Donnenfeld, Shabtai & White, Lawrence J, 1988. "The Multiproduct Firm, Quality Choice, and Regulation," Journal of Industrial Economics, Wiley Blackwell, vol. 36(4), pages 411-429, June.
- Patricia Danzon, 1997. "Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 4(3), pages 301-322.
- Michael Spence, 1973. "Job Market Signaling," The Quarterly Journal of Economics, Oxford University Press, vol. 87(3), pages 355-374.
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Simone Ghislandi & Michael Kuhn, 2016.
"Asymmetric information in the regulation of the access to markets,"
Department of Economics Working Papers
wuwp219, Vienna University of Economics and Business, Department of Economics.
- Ghislandi, Simone & Kuhn, Michael, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Paper Series 4886, WU Vienna University of Economics and Business.
More about this item
- I1 - Health, Education, and Welfare - - Health
- L51 - Industrial Organization - - Regulation and Industrial Policy - - - Economics of Regulation
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
NEP fieldsThis paper has been announced in the following NEP Reports:
- NEP-ALL-2008-12-21 (All new papers)
- NEP-COM-2008-12-21 (Industrial Competition)
- NEP-HEA-2008-12-21 (Health Economics)
- NEP-IND-2008-12-21 (Industrial Organization)
- NEP-MIC-2008-12-21 (Microeconomics)
- NEP-REG-2008-12-21 (Regulation)
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:14567. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: () or (Joanne Lustig). General contact details of provider: http://edirc.repec.org/data/nberrus.html .
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.